Characteristic | Guselkumab response continuation | Guselkumab non-response continuation | Guselkumab response withdrawal | Adalimumab withdrawal | Adalimumab to guselkumab |
---|---|---|---|---|---|
Randomized patients | n = 108 | n = 63 | n = 101 | n = 65 | n = 67 |
Age, years | |||||
Mean ± S.D | 44.4 ± 12.3 | 44.6 ± 10.9 | 42.2 ± 10.3 | 43.8 ± 11.3 | 44.1 ± 11.0 |
Men, n (%) | 76 (70.4) | 52 (82.5) | 76 (75.2) | 41 (63.1) | 47 (70.1) |
Race, n (%) | |||||
White | 91 (84.3) | 50 (79.4) | 90 (89.1) | 55 (84.6) | 59 (88.1) |
Asian | 14 (13.0) | 9 (14.3) | 10 (9.9) | 8 (12.3) | 7 (10.4) |
Black | 0 | 2 (3.2) | 1 (1.0) | 1 (1.5) | 1 (1.5) |
BMI, kg/m2 | |||||
Mean ± S.D | 29.9 ± 5.8 | 31.6 ± 6.5 | 29.3 ± 6.2 | 28.9 ± 6.1 | 31.3 ± 6.2 |
Smoking status, n (%) | |||||
Current smoker | 36 (33.3) | 15 (23.8) | 39 (38.6) | 18 (27.7) | 32 (47.8) |
Former smoker | 21 (19.4) | 13 (20.6) | 20 (19.8) | 14 (21.5) | 15 (22.4) |
Never smoker | 51 (47.2) | 35 (55.6) | 42 (41.6) | 33 (50.8) | 20 (29.9) |
Duration of psoriasis, years | |||||
Mean ± S.D | 19.6 ± 12.4 | 20.1 ± 11.8 | 17.8 ± 11.7 | 18.6 ± 12.1 | 18.3 ± 12.2 |
BSA involvement, % | |||||
Mean ± S.D | 28.4 ± 16.5 | 30.8 ± 19.7 | 29.0 ± 15.7 | 30.4 ± 15.7 | 26.3 ± 16.9 |
IGA score, 0–4, n (%) | |||||
Moderate, 3 | 85 (78.7) | 43 (68.3) | 76 (75.2) | 56 (86.2) | 50 (74.6) |
Severe, 4 | 23 (21.3) | 20 (31.7) | 25 (24.8) | 9 (13.8) | 17 (25.4) |
PASI, 0–72 | |||||
Mean ± S.D | 22.6 ± 8.8 | 23.1 ± 9.8 | 23.2 ± 9.0 | 22.7 ± 8.6 | 20.1 ± 8.5 |
NAPSI, 0–8 | n = 108 | n = 61 | n = 97 | n = 62 | n = 66 |
Mean ± S.D | 4.4 ± 1.8 | 4.9 ± 2.0 | 5.0 ± 2.1 | 4.7 ± 1.9 | 4.2 ± 1.9 |
Nail bed score | n = 108 | n = 61 | n = 97 | n = 62 | n = 66 |
Mean ± S.D | 1.9 ± 1.2 | 2.1 ± 1.3 | 2.2 ± 1.2 | 2.1 ± 1.1 | 2.0 ± 1.0 |
Nail matrix score | n = 107 | n = 61 | n = 97 | n = 62 | n = 66 |
Mean ± S.D | 2.5 ± 1.2 | 2.7 ± 1.2 | 2.7 ± 1.3 | 2.6 ± 1.2 | 2.2 ± 1.4 |
f-PGA, 0–4, n (%) | |||||
Minimal, 1 | 18 (16.7) | 6 (9.8) | 10 (10.2) | 5 (8.1) | 10 (15.4) |
Mild, 2 | 37 (34.3) | 15 (24.6) | 35 (35.7) | 23 (37.1) | 23 (35.4) |
Moderate, 3 | 42 (38.9) | 30 (49.2) | 45 (45.9) | 26 (41.9) | 30 (46.2) |
Severe, 4 | 11 (10.2) | 10 (16.4) | 7 (7.1) | 8 (12.9) | 2 (3.1) |
Psoriatic arthritis, n (%) | 21 (19.4) | 16 (25.4) | 27 (26.7) | 17 (26.2) | 17 (25.4) |
Prior treatments | |||||
Topical agents | 102 (94.4) | 56 (88.9) | 101 (100.0) | 62 (95.4) | 65 (97.0) |
Phototherapy | 67 (62.0) | 44 (69.8) | 64 (63.4) | 35 (53.8) | 34 (50.7) |
Conventional systemic agents | 60 (55.6) | 48 (76.2) | 65 (64.4) | 40 (61.5) | 46 (68.7) |
Biologic agents | 23 (21.3) | 17 (27.0) | 16 (15.8) | 10 (15.4) | 12 (17.9) |
DLQI, 0–30 | n = 107 | n = 63 | n = 101 | n = 64 | n = 67 |
Mean ± S.D | 14.3 ± 6.4 | 16.0 ± 8.0 | 14.5 ± 6.1 | 15.2 ± 6.1 | 15.3 ± 8.0 |